ES2075885T3 - Forma polimorfa estable de (e)-n,n-dietil-2-ciano-3-(3,4-dihidroxi-5-nitrofenil)acrilamida y el proceso para su preparacion. - Google Patents

Forma polimorfa estable de (e)-n,n-dietil-2-ciano-3-(3,4-dihidroxi-5-nitrofenil)acrilamida y el proceso para su preparacion.

Info

Publication number
ES2075885T3
ES2075885T3 ES90311963T ES90311963T ES2075885T3 ES 2075885 T3 ES2075885 T3 ES 2075885T3 ES 90311963 T ES90311963 T ES 90311963T ES 90311963 T ES90311963 T ES 90311963T ES 2075885 T3 ES2075885 T3 ES 2075885T3
Authority
ES
Spain
Prior art keywords
acrylamide
diethyl
polymorphic form
nitrophenil
dihidroxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90311963T
Other languages
English (en)
Inventor
Aino Kyllikki Pippuri
Erkki Juhani Honkanen
Jorma Veikko Haarala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10665678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2075885(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Application granted granted Critical
Publication of ES2075885T3 publication Critical patent/ES2075885T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

UNA FORMA POLIMORFICA CRISTALOGRAFICA Y ESENCIALMENTE PURA Y ESTABLE A DE (E)-N, N-DIETIL-2-CIANO-3-(3, 4-DIHIDROXI-5-NITRO-FENIL) ACRILAMIDA PUEDEN PREPARARSE CRISTALIZANDO UN PRODUCTO DE SINTESIS EN CRUDO DESDE UN ACIDO CARBOXILICO ALIFALICO COMO ACIDO FORMICO O ACETICO CON UNA CANTIDAD CATALITICA DE ACIDO HIDROCLORICO O HIDROBROMICO AÑADIDO. EL PRODUCTO ES UN POTENTE INHIBIDOR DE ENZIMA CATECOL-O-METILO-TRANSFERASA (COMT).
ES90311963T 1989-11-03 1990-11-01 Forma polimorfa estable de (e)-n,n-dietil-2-ciano-3-(3,4-dihidroxi-5-nitrofenil)acrilamida y el proceso para su preparacion. Expired - Lifetime ES2075885T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8924838A GB2238047B (en) 1989-11-03 1989-11-03 Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation

Publications (1)

Publication Number Publication Date
ES2075885T3 true ES2075885T3 (es) 1995-10-16

Family

ID=10665678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90311963T Expired - Lifetime ES2075885T3 (es) 1989-11-03 1990-11-01 Forma polimorfa estable de (e)-n,n-dietil-2-ciano-3-(3,4-dihidroxi-5-nitrofenil)acrilamida y el proceso para su preparacion.

Country Status (13)

Country Link
US (1) US5135950A (es)
EP (1) EP0426468B1 (es)
JP (1) JP2823680B2 (es)
AT (1) ATE127447T1 (es)
BR (1) BR1100289A (es)
DE (2) DE122004000014I1 (es)
DK (1) DK0426468T3 (es)
ES (1) ES2075885T3 (es)
FI (1) FI107149B (es)
GB (1) GB2238047B (es)
GR (1) GR3017526T3 (es)
LU (1) LU91071I2 (es)
NL (1) NL300147I1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
GB9113431D0 (en) * 1991-06-20 1991-08-07 Orion Yhytma Oy Method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
PL1697394T3 (pl) * 2003-12-19 2007-08-31 Hoffmann La Roche Inhibitory COMT
AU2003296838A1 (en) * 2003-12-24 2005-08-11 Siddiqui Mohammed Jaweed Mukarram An efficient process for the manufacture of (e)-entacapone polymorphic form a
BR0318690A (pt) * 2003-12-29 2006-12-26 Wockhardt Ltd polimorfos estáveis de (e)-n,n-dietil-2-ciano-3-(3,4-dihidróxi-5-nitrofenil)acril amida
AU2003287844A1 (en) * 2003-12-31 2005-07-21 Cilag Ag Novel crystalline forms of entacapone, and production thereof
WO2005063696A2 (de) * 2003-12-31 2005-07-14 Cilag Ag Neue kristalline formen von entacapone und deren herstellung
EP1577289A1 (en) 2004-03-18 2005-09-21 Revotar Biopharmaceuticals AG Non-glycosylated/-glycosidic/-peptidic small molecule selectin inhibitors for the treament of inflammatory disorders
CA2570884C (en) * 2004-06-16 2016-04-19 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
PL1896006T3 (pl) 2005-06-08 2010-03-31 Orion Corp Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
EP1764093A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel aromatic compounds and their use in medical applications
EP1764096A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel phloroglucinol derivatives having selectin ligand activity
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
ATE445591T1 (de) * 2005-11-09 2009-10-15 Usv Ltd Verfahren zur herstellung von hochreinem (e)-n,n- diethyl-2-cyano-3-(3,4-dihydro-5- nitrophenyl)acrylamid (entacapon)
CN101460451A (zh) * 2006-01-02 2009-06-17 阿克塔维什集团Ptc公司 A型恩他卡朋的制备方法
CA2641396C (en) * 2006-02-06 2014-07-22 Orion Corporation Process for manufacturing entacapone
WO2007094007A1 (en) * 2006-02-13 2007-08-23 Suven Life Sciences Ltd., An improved process for the preparation of entacapone
WO2007113845A1 (en) * 2006-04-03 2007-10-11 Alembic Limited A process for the preparation of (e)-2-cyano-3-(3, 4-dihydroxy-5-nitrophenyl)-n, n-diethyl-2-propenamide (entacapone)
GB0610207D0 (en) * 2006-05-23 2006-07-05 Pliva Istrazivanje I Razvoj D New forms of active pharmaceutical ingredient
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US20080004343A1 (en) * 2006-06-29 2008-01-03 Wockhardt Limited Stable polymorphs of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
GB0613826D0 (en) * 2006-07-12 2006-08-23 Pliva Istrazivanje I Razvoj D Process and product
ES2306587B1 (es) * 2006-11-15 2009-08-07 Quimica Sintetica, S.A. Nueva forma cristalina de entacapona y procedimiento para su obtencion.
ITMI20062450A1 (it) 2006-12-19 2008-06-20 Dipharma Spa Procedimento per la preparazione di entacapone
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
ES2319024B1 (es) * 2007-02-13 2009-12-11 Quimica Sintetica, S.A. Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina.
WO2009084031A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd An improved process for preparation of (2e)-2-cyano-3-(3,4- dihydroxy-5-nitrophenyl)n,n-diethyl-2-propenamide polymorphic form a
EP2251323B1 (en) 2009-05-14 2014-04-23 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Method for the purification of entacapone
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
CN103845317B (zh) 2012-11-28 2018-05-08 北京生命科学研究所 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN104402764A (zh) * 2014-11-26 2015-03-11 千辉药业（安徽）有限责任公司 一种恩他卡朋的制备方法
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US4971996A (en) * 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
DE68917357T2 (de) * 1988-04-28 1995-01-26 Suntory Ltd Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten.
GB8813762D0 (en) 1988-06-10 1988-07-13 Orion Yhtymae Oy Catechol derivatives for use in cancer treatment
JP2535058B2 (ja) * 1988-07-29 1996-09-18 富士通株式会社 半導体装置の製造方法

Also Published As

Publication number Publication date
EP0426468B1 (en) 1995-09-06
FI905198A0 (fi) 1990-10-23
DK0426468T3 (da) 1995-10-23
ATE127447T1 (de) 1995-09-15
LU91071I2 (fr) 2005-06-21
GB8924838D0 (en) 1989-12-20
GB2238047A (en) 1991-05-22
DE69022166D1 (de) 1995-10-12
JP2823680B2 (ja) 1998-11-11
NL300147I1 (nl) 2004-07-01
US5135950A (en) 1992-08-04
FI107149B (fi) 2001-06-15
EP0426468A3 (en) 1992-05-06
GB2238047B (en) 1993-02-10
EP0426468A2 (en) 1991-05-08
BR1100289A (pt) 1999-10-05
JPH03169844A (ja) 1991-07-23
GR3017526T3 (en) 1995-12-31
DE69022166T2 (de) 1996-02-15
DE122004000014I1 (de) 2004-08-12

Similar Documents

Publication Publication Date Title
ES2075885T3 (es) Forma polimorfa estable de (e)-n,n-dietil-2-ciano-3-(3,4-dihidroxi-5-nitrofenil)acrilamida y el proceso para su preparacion.
FR2710638B1 (fr) Procédé de préparation d'isomères d'acides benzènedicarboxyliques de haute pureté.
IS5883A (is) Aðferð til framleiðslu á hreinu sítalóprami
AU3670100A (en) Catalyst for production of acetic acid or acetic acid and ethyl acetate, processfor its production and process for production of acetic acid or acetic acid and ethyl acetate using it
BG106219A (bg) Метод за получаване на чист циталопрам
IL116281A (en) Process for the purification of (rr,ss)-2-dimethylaminomethyl-1-(3-methoxyphenyl) cyclohexanol and its salts
DE60117860D1 (de) Kristallisierungsverfahren zur herstellung von sehr reinem para-xylol
DE69517201D1 (de) Verfahren zur herstellung von 2-(2-hydroxymethylphenyl)acetamid-derivaten und zwischenprodukte zur herstellung
DE69028938D1 (de) Verfahren zur Reinigung von 3-alpha-7-beta-Dihydroxycholansäure
ATE319722T1 (de) Verfahren zur herstellung von vitamin-d analogen
KR930019599A (ko) α,β-불포화카르복실산의 제조방법
RU93001121A (ru) Способ получения очищенной 2,4-дихлорфеноксиуксусной кислоты
CA2200607A1 (en) Processes and intermediates for preparing 5,7-dihydro-3-[2-{1-benzylpiperidin-4-yl}ethyl]-6h-pyrrolo-[4,5-f]-1,2-benzisoxazol-6-one
JPS6445334A (en) 2-(r)-halogeno-4-phenyl lactic acid derivative and production thereof
DE69407938D1 (de) Verfahren zur herstellung von alpha-hydroximinophenylacetonitril
EP1035097A4 (en) PROCESS FOR THE PREPARATION OF SORBIC ACID
JPS56118022A (en) Di 3,3,3-trifluoropropyl derivative of 1,2-diphenylethane

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 426468

Country of ref document: ES

SPCR Supplementary protection certificate renounced

Free format text: REGISTRY NO/DATE: EU/1/03/260/001-012 20031017, SC="C200400008"

Filing date: 20040416